Abstract
Background: Although medical guidelines discourage the use of methylxanthines in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), they are still widely used in clinical practice. This study investigated the real-world use of methylxanthines in the management of AECOPD. Methods: Patient data from the Acute exacerbation of Chronic obstructive pulmonary disease Using REgistry data (ACURE, NCT02657525) study database were screened. Enrolled patients were divided into treatment and control groups. Propensity score (PS) matching and Cox regression analyses were used to minimize confounding factors and determine the association between methylxanthine treatment and the length of stay (LOS). Results: Among the 2088 eligible patients, 1,563 (74.9%) were in the methylxanthine treatment group. Patients treated with methylxanthines had more severe respiratory symptoms and worse lung function than those in the control group. Doxophylline was the most commonly used methylxanthine in both secondary and tertiary hospitals. After PS matching, 966 patients were equally divided into two groups. The LOS of patients in the two groups was similar [median: 8 days, interquartile range (IQR): 7–11 days, p = 0.730]. Patients in the treatment group (median: 8, IQR: 4–12) had a more significant decrease in the COPD Assessment Test score from admission to discharge than those in the control group (median: 6, IQR: 2–10, p < 0.001). Among all matched patients, the LOS was not significantly associated with methylxanthine treatment [adjusted hazard ratio (HR): 1.02, 95% confidence intervals (CIs): 0.89–1.16]. However, in the subgroup analysis, methylxanthines were significantly associated with a short LOS in patients with blood eosinophil count >4% (adjusted HR: 1.56, 95% CIs: 1.12–2.17). Conclusion: This study revealed that methylxanthines, especially doxophylline, are widely used in China. Methylxanthines were effective in improving symptoms in AECOPD patients. Higher blood eosinophil count may be associated with a better efficacy of methylxanthine treatment.
Highlights
Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory symptoms and persistently inadequate airflow
We found that a large number of hospitalized Acute exacerbation of COPD (AECOPD) patients around China received methylxanthine treatment
This study revealed that methylxanthines, especially doxophylline, are widely used in China for the treatment of AECOPD
Summary
Chronic obstructive pulmonary disease (COPD) is characterized by chronic respiratory symptoms and persistently inadequate airflow. Effective pharmacological treatments are required to minimize the impact of this condition on patients’ health and well-being Methylxanthines, such as theophylline, have been used in the treatment of COPD and asthma for more than 80 years. Previous randomized control trials on methylxanthine treatment for AECOPD have indicated frequent side effects and drug interactions (Barr et al, 2003; Duffy et al, 2005). Based on these results, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) does not recommend the use of methylxanthines in AECOPD patients. This study investigated the real-world use of methylxanthines in the management of AECOPD
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
